LUF6096|cas:1116652-18-6|西域试剂

LUF6096,99.00%

产品编号：Bellancom-10915| CAS NO：1116652-18-6| 分子式：C₂₂H₂₁Cl₂N₃O| 分子量：414.33

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-10915	￥2500.00	杭州北京（现货）
Bellancom-10915	￥4000.00	杭州北京（现货）
Bellancom-10915	￥8000.00	杭州北京（现货）
Bellancom-10915	￥13000.00	杭州北京（现货）
Bellancom-10915	￥19500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LUF6096

产品介绍

LUF6096 是一种有效的腺苷 A3 受体 (adenosine A3 receptor) 变构增强剂。LUF6096 对任何腺苷受体显示出低正构亲和力。LUF6096 在心肌缺血/再灌注损伤中显示出保护作用。

生物活性

LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury.

体外研究

LUF6096 (10 μM; 30-120 min) decreases the dissociation rate of ¹²⁵I-AB-MECA from the A₃ receptor by 2.5 times in CHO cell membranes.
LUF6096 (10 μM; pretreated for 15 min) significantly and dramatically enhances the intrinsic activity of Cl-IB-MECA for the inhibition of the forskolin-stimulated cAMP production in CHO cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

LUF6096 (twice i.v. bolus for 0.5 mg/kg or single i.v. bolus for 1 mg/kg) protects against myocardial ischemia/reperfusion injury in dogs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult mongrel dogs (15-25 kg) were subjected left anterior descending (LAD) coronary artery occlusion and reperfusion
Dosage:	Twice i.v. bolus for 0.5 mg/kg or single i.v. bolus for 1 mg/kg
Administration:	I.v. bolus
Result:	Produced a marked reduction in infarct size (∼50% reduction) compared with vehicle-treated dogs.

体内研究

LUF6096 (twice i.v. bolus for 0.5 mg/kg or single i.v. bolus for 1 mg/kg) protects against myocardial ischemia/reperfusion injury in dogs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult mongrel dogs (15-25 kg) were subjected left anterior descending (LAD) coronary artery occlusion and reperfusion
Dosage:	Twice i.v. bolus for 0.5 mg/kg or single i.v. bolus for 1 mg/kg
Administration:	I.v. bolus
Result:	Produced a marked reduction in infarct size (∼50% reduction) compared with vehicle-treated dogs.

性状

Solid

溶解性数据

In Vitro:

DMSO : 20 mg/mL (48.27 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4135 mL	12.0677 mL	24.1354 mL
5 mM	0.4827 mL	2.4135 mL	4.8271 mL
10 mM	0.2414 mL	1.2068 mL	2.4135 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2 mg/mL (4.83 mM); Clear solution

此方案可获得 ≥ 2 mg/mL (4.83 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。